Shopping Cart 0
Cart Subtotal
AED 0

Global Injectable Drug Delivery Market Analysis, Companies Profiles, Size, Share, Growth, Trends and Forecast to 2025

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 15414

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 19818
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Global injectable drug delivery market is expected to reach USD 1,104,096.5 million by 2025 from USD 378,998.2 million in 2017, at a CAGR of 12.4% in the forecast period 2018 to 2025

The major factors contributing to the growth of the market includes factors such rising cases of chronic diseases and due to rising demand of self-injection devices. On the other hand needle stick injuries and infections may hinder the growth of the market.

The key market players for global injectable drug delivery market are listed below:

Baxter International, Inc.,

Becton Dickinson and Company,

Gerresheimer AG,

Pfizer, Inc.,

Schott AG,

Alkermes Plc.,

Eli Lilly and Company,

Sandoz,

Terumo Corporation,

Teva Pharmaceuticals Industries Ltd.

Ypsomed,

Bespak

The market is further segmented into:

Type

Usage Pattern

End-User

Mode of Administration

Distribution Channel

Application

Geography

The global injectable drug delivery market is segmented on of type, portability, type, product type, application, usage pattern, mode of administration, end user, distribution channel, and geography. The report provides data for 2016 to 2025, 2017 being the current year while 2018 to 2025 is the forecast period for the report.

The global injectable drug delivery market is segmented based on type into two notable segments; injectable drug delivery device and injectable drug delivery formulation. Injectable drug delivery device market is segmented into conventional injection devices and self-injection devices. The injectable drug delivery formulation is segmented into conventional drug delivery formulation and novel drug delivery formulation. The Injectable drug delivery market is dominated by formulations with 75.7% market share in 2018, growing at a CAGR of 12.4% and will cross USD 837,873.64 million by 2025

On the basis of application, the market is segmented into autoimmune disease, hormonal disorders, orphan diseases, oncology and others. The autoimmune diseases segment is further sub segmented based on indications into rheumatoid arthritis, multiple sclerosis, Crohn's disease, psoriasis and others. Hormonal disorders are further segmented into indications such as diabetes, antithrombotic therapy, reproductive health diseases, anemia, osteoporosis and others. The Injectable drug delivery market is dominated by hormonal disorders with 50.1% market share in 2018, growing at a CAGR of 12.1% and will cross USD 540,977.35 million by 2025. However, oncology segment is expected to grow at the highest CAGR of 13.6% in the forecast period, and is expected to reach USD 265,145.17 million in 2025 from USD 82,915.00 million in 2017

On the basis of usage pattern, the market is segmented into curative care, immunization and other usage pattern. The Injectable drug delivery market is dominated by curative care with 93.2% market share in 2018, growing at a CAGR of 12.5% and will cross USD 1,036,829.49 million by 2025.

On the basis of mode of administration, the market is segmented into skin, circulatory/muskoskeletal, organs and central nervous system. The Injectable drug delivery market is dominated by skin with 46.8% market share in 2018, growing at a CAGR of 12.8% and will cross USD 532,193.0 million by 2025.

On the basis of end users, the market is classified into hospitals and clinics, home healthcare, research laboratories, pharmaceutical and biotechnological companies and others. The Injectable drug delivery market is dominated by hospitals & clinics with 62.6% market share in 2018, growing at a CAGR of 12.5% and will cross USD 693,323.05 million by 2025.

On the basis of distribution channel, the market is classified into hospital pharmacies, pharmacy store, and direct tender and online pharmacy. The Injectable drug delivery market is dominated by direct tenders with 69.2% market share in 2018, growing at a CAGR of 12.7% and will cross USD 780,682.75 million by 2025. However, pharmacy stores segment is expected to grow at the highest CAGR of 13.5% in the forecast period, and is expected to reach USD 142,617.48 million in 2025 from USD 44,812.56 million in 2017

Based on geography, the market is segmented into 5 geographical regions, North America, Europe, Asia-Pacific, South America and Middle East and Africa. The geographical regions are further segmented into 24 major countries such as U.S. Canada, Mexico, Germany, France, U.K., Belgium, Switzerland, Belgium, Turkey, Japan, China, Singapore, Brazil, India, Russia, South Africa and many others.

Based on geography, the Global injectable drug delivery market is segmented into geographical regions, such as,

North- America

South America

Europe

Asia-Pacific

Middle East and Africa

Covered in this report

The report covers the present scenario and the growth prospects of the global injectable drug delivery market for 2018-2025. To calculate the market size, the report considers the revenue generated from the sales of the web conferencing and unified communication and collaboration (UC&C) and video conferencing, secondary resources and doing in-depth company share analysis of major 10 players in the market.

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

READ MORE

Table Of Content

Scope

Table Of Contents

1 Introduction 58

1.1 Overview Of Global Injectable Drug Delivery Market 58

1.2 Currency And Pricing 59

1.3 Limitation 59

1.4 Markets Covered 60

2 Market Segmentation 63

2.1 Markets Covered 63

2.2 Geographic Scope 64

2.3 Years Considered For The Study 65

2.4 Currency And Pricing 65

2.5 Research Methodology 66

2.6 Primary Interviews With Key Opinion Leaders 69

2.7 Secondary Sources 70

2.8 Assumptions 70

3 Market Overview 71

3.1 Drivers 73

3.1.1 Rising Cases Of Chronic Diseases 73

3.1.2 Rising Demand Of Self-Injection Devices 75

3.1.3 Growth Of Biologics Market 75

3.1.4 Technological Advancements And Innovations In Drug Delivery Market 76

3.2 Restraints 77

3.2.1 Needlestick Injuries And Infections 77

3.2.2 High Cost Of Development 78

3.2.3 Strict Regulatory Framework 79

3.3 Opportunity 80

3.3.1 Increasing Demand For Generic And Biosimilar Drugs 80

3.3.1.1 Generics 80

3.3.1.2 Biosimilars 80

3.3.2 Increasing Demand For Contraceptive Injectables 81

3.3.3 Increasing Demand For Self-Administration Of Drugs 82

3.4 Challenges 83

3.4.1 Alternative Route Of Drug Administration 83

3.4.2 Product Recall 84

3.4.3 Stability Of Products 84

3.4.4 Sterility Of Injections 85

4 Executive Summary 86

5 Premium Insights 88

?

6 Global Injectable Drug Delivery Market, By Type 91

6.1 Overview 92

6.2 Injectable Drug Delivery Devices 93

6.2.1 Conventional Injection Devices 94

6.2.1.1 Conventional Injection Devices, By Material 94

6.2.1.1.1 Glass 95

6.2.1.1.2 Plastic 95

6.2.1.2 Conventional Injection Devices, By Product 96

6.2.1.2.1 Fillable Syringes 96

6.2.1.2.2 Prefilled Syringes 96

6.2.1.3 Conventional Injection Devices, By Usability 98

6.2.1.3.1 Reusable Syringes 98

6.2.1.3.2 Disposable Syringes 98

6.2.2 Self Injection Devices 99

6.2.2.1 Needle Free Injectors (Nfi) 100

6.2.2.2 Needle Free Injectors, By Product 101

6.2.2.2.1 Fillable Needle-Free Injectors 101

6.2.2.2.2 Prefilled Needle-Free Injectors 101

6.2.2.3 Needle Free Injectors, By Technology 101

6.2.2.3.1 Jet Based Needle Free Injectors: 102

6.2.2.3.2 Spring Based Needle Free Injectors: 102

6.2.2.3.3 Laser Based Needle Free Injectors: 103

6.2.2.3.4 Vibration Based Needle Free Injectors: 103

6.2.2.4 Needle Free Injectors, By Usability 103

6.2.2.4.1 Reusable Needle-Free Injectors 103

6.2.2.4.2 Disposable Needle-Free Injectors 104

6.2.2.5 Auto Injectors 105

6.2.2.6 Auto Injectors, By Product 105

6.2.2.6.1 Fillable Auto Injectors 105

6.2.2.6.2 Pre-Filled Autoinjectors 105

6.2.2.7 Auto Injectors, By Technology 106

6.2.2.7.1 Automated Auto Injectors 106

6.2.2.7.2 Manual Auto Injectors 106

6.2.2.8 Auto Injectors, By Design 107

6.2.2.8.1 Standardized Auto Injectors 107

6.2.2.8.2 Automated Autoinjectors 107

6.2.2.9 Auto Injectors, By Usability 108

6.2.2.9.1 Reusable Autoinjectors 108

6.2.2.9.2 Disposable Autoinjectors 108

6.2.2.10 Pen Injectors 109

?

6.2.2.11 Pen Injectors, By Product 109

6.2.2.11.1 Single Chambered Pen Injectors 110

6.2.2.11.2 Dual Chambered Pen Injectors 110

6.2.2.12 Pen Injectors, By Design 111

6.2.2.12.1 Standard Pen Injectors 111

6.2.2.12.2 Customized Pen Injectors 111

6.2.2.13 Pen Injectors, By Usability 111

6.2.2.13.1 Reusable Pen Injectors 111

6.2.2.13.2 Disposable Pen Injectors 112

6.2.2.14 Wearable Injectors 113

6.2.2.14.1 Other Devices 113

6.3 Injectable Drug Delivery Formulation 114

6.3.1 Conventional Drug Delivery Formulations 114

6.3.1.1 Solutions 115

6.3.1.2 Reconstituted/Lyophilized Formulations 115

6.3.1.3 Suspensions 116

6.3.1.4 Emulsions 117

6.3.2 Novel Drug Delivery Formulations 118

6.3.2.1 Colloidal Dispersions 120

6.3.2.1.1 Niosomes 121

6.3.2.1.2 Liposomes 121

6.3.2.1.3 Polymeric Mixed Micelles 122

6.3.2.1.4 Nanoparticles 123

6.3.2.1.5 Nanosuspensions 124

6.3.2.1.6 Nanoemulsions/Microemulsions 124

6.3.2.1.7 Solid Lipid Nanoparticles 125

6.3.2.2 Microparticles 126

6.3.2.2.1 Microspheres 126

6.3.2.2.2 Microcapsules 127

6.3.2.3 Long Acting Injection Formulation 128

7 Global Injectable Drug Delivery Market, By Application 130

7.1 Overview 131

7.2 Global Injectable Drug Delivery Market, By Application 132

7.3 Hormonal Disorders 133

7.3.1 Injectable Drugs For Diabetes 133

7.3.2 Injectable Drugs For Anemia 134

7.3.3 Injectable Drugs For Reproductive Health Disease 134

7.3.4 Injectable Drugs For Antithrombotic/Thrombolytic Therapy 136

7.3.5 Injectable Drugs For Osteoporosis 136

7.3.6 Injectable Drugs For Growth Hormone Disorders (Ghd) 137

?

7.4 Oncology 139

7.5 Autoimmune Diseases 141

7.5.1 Injectable Drugs For Rheumatoid Arthritis 141

7.5.2 Injectable Drugs For Multiple Sclerosis 142

7.5.3 Injectable Drugs For Crohn'S Diseases 143

7.5.4 Injectable Drugs For Psoriasis 144

7.5.5 Injectable Drugs For Other Autoimmune Diseases 145

7.6 Orphan Disease 146

7.7 Other Applications 148

7.7.1 Injectable Drugs For Pain Management 148

7.7.2 Injectable Drugs For Allergy Treatment 149

7.7.3 Injectable Drugs For Aesthetic Treatments 150

7.7.4 Injectable Drugs For Hepatitis C 151

7.7.5 Injectable Drugs For Hemophilia 152

8 Global Injectable Drug Delivery Market, By Usage Pattern 154

8.1 Overview 155

8.2 Curative Care 156

8.3 Immunizations 157

8.4 Other Usage Pattern 157

9 Global Injectable Drug Delivery Market, By Mode Of Administration 159

9.1 Overview 160

9.2 Skin 161

9.3 Circulatory/ Muskoskeletal 161

9.4 Organs 162

9.5 Central Nervous System 162

10 Global Injectable Drug Delivery Market, By End User 164

10.1 Overview 165

10.2 Hospitals And Clinics 167

10.3 Home Healthcare Settings 167

10.4 Research Laboratories 167

10.5 Pharmaceutical And Biotechnological Companies 168

10.6 Other End Users 169

11 Global Injectable Drug Delivery Market, By Distribution Channel 170

11.1 Overview 171

11.1.1 Hospital Pharmacy 172

11.1.2 Pharmacy Stores 172

11.1.3 Direct Tender 172

11.1.4 Online Pharmacy 172

?

12 Global Injectable Drug Dilivery Market By Geography 174

12.1 Overview 174

12.2 North America 176

12.2.1 U.S. 194

12.2.2 Canada 209

12.2.3 Mexico 225

12.3 Europe 241

12.3.1 Germany 259

12.3.2 France 274

12.3.3 U.K. 291

12.3.4 Italy 306

12.3.5 Switzerland 322

12.3.6 Spain 338

12.3.7 Netherland 354

12.3.8 Russia 371

12.3.9 Turkey 385

12.3.10 Belgium 400

12.3.11 Rest Of Europe 417

12.4 Asia-Pacific 418

12.4.1 Japan 436

12.4.2 China 452

12.4.3 India 467

12.4.4 South Korea 482

12.4.5 Australia 497

12.4.6 Thailand 512

12.4.7 Malaysia Injectable Drug Delivery Market 528

12.4.8 Singapore 543

12.4.9 Indonesia 558

12.4.10 Phillippines 573

12.4.11 Rest Of Asia-Pacific Injectable Drug Delivery Market 588

12.5 South America 589

12.5.1 Brazil 606

12.5.2 Rest Of South Africa 622

12.6 Middle East & Africa 623

12.6.1 South Africa Injectable Drug Delivery Market 640

12.6.2 Rest Of Middle East& Africa Injectable Drug Delivery Market 656

13 Global Injectable Drug Delivery Market, Company Share 657

13.1 Company Share Analysis: Global 657

?

14 Company Profiles 658

14.1 Becton, Dickinson And Company 658

14.1.1 Company Overview 658

14.1.1.1 Drivers Explained 659

14.1.1.2 Weaknesses Explained 659

14.1.1.3 Oppurtunities Explained 659

14.1.1.4 Threats Explained 660

14.1.2 Becton, Dickinson And Company: Revenue Analysis 660

14.1.3 Product Portfolio 662

14.1.4 Recent Developments 663

14.2 Pfizer 665

14.2.1 Company Overview 665

14.2.1.1 Drivers Explained 666

14.2.1.2 Weaknesses Explained 666

14.2.1.3 Oppurtunities Explained 667

14.2.1.4 Threats Explained 668

14.2.2 Pfizer, Inc.: Revenue Analysis 668

14.2.3 Product Portfolio 669

14.2.4 Recent Developments 671

14.3 Baxter International, Inc. 674

14.3.1 Company Overview 674

14.3.1.1 Drivers Explained 675

14.3.1.2 Weaknesses Explained 676

14.3.1.3 Oppurtunities Explained 676

14.3.1.4 Threats Explained 676

14.3.2 Baxter International: Revenue Analysis 677

14.3.3 Product Portfolio 679

14.3.4 Recent Developments 679

14.4 Gerresheimer Ag 681

14.4.1 Company Overview 681

14.4.2 Gerresheimer Ag: Revenue Analysis 681

14.4.3 Product Portfolio 682

14.4.4 Recent Developments 682

14.5 Schott Ag Inc. 683

14.5.1 Company Overview 683

14.5.2 Schott Ag Inc: Revenue Analysis 683

14.5.3 Product Portfolio 684

14.5.4 Recent Developments 684

?

14.6 Alkermes Inc. 686

14.6.1 Company Overview 686

14.6.2 Alkermes Inc.: Revenue Analysis 686

14.6.3 Product Portfolio 686

14.6.4 Recent Developments 687

14.7 Antares Pharma 689

14.7.1 Company Overview 689

14.7.2 Antares Pharma: Revenue Analysis 689

14.7.3 Product Portfolio 690

14.7.4 Recent Developments 691

14.8 Bespak (Subsidiary Of Consort Medical Company) 692

14.8.1 Company Overview 692

14.8.2 Bespak (Subsidiary Of Consort Medical Company): Revenue Analysis 692

14.8.3 Product Portfolio 693

14.8.4 Recent Developments 693

14.9 Elcam Medical 695

14.9.1 Company Overview 695

14.9.2 Elcam Medical: Company Snapshot 695

14.9.3 Product Portfolio 696

14.9.4 Recent Developments 696

14.10 Eli Lilly And Company 697

14.10.1 Company Overview 697

14.10.1.1 Drivers Explained 698

14.10.1.2 Weaknesses Explained 698

14.10.1.3 Oppurtunities Explained 699

14.10.1.4 Threats Explained 700

14.10.2 Eli Lilly And Company : Revenue Analysis 700

14.10.3 Product Portfolio 702

14.10.4 Recent Developments 703

14.11 Haselmeier 705

14.11.1 Company Overview 705

14.11.2 Haselmeier: Company Snapshot 705

14.11.3 Product Portfolio 705

14.11.4 Recent Developments 706

14.12 Mylan N.V. 707

14.12.1 Company Overview 707

14.12.2 Mylan N.V.: Revenue Analysis 707

14.12.3 Product Portfolio 708

14.12.4 Recent Developments 708

?

14.13 Novo Nordisk 711

14.13.1 Company Overview 711

14.13.2 Novo Nordisk: Revenue Analysis 711

14.13.3 Product Portfolio 712

14.13.4 Recent Developments 713

14.14 Owen Mumford Ltd 715

14.14.1 Company Overview 715

14.14.2 Owen Mumford Ltd: Company Snapshot 715

14.14.3 Product Portfolio 716

14.14.4 Recent Developments 716

14.15 Sandoz International Gmbh 718

14.15.1 Company Overview 718

14.15.2 Sandoz International Gmbh: Revenue Analysis 718

14.15.3 Product Portfolio 718

14.15.4 Recent Developments 719

14.16 Sanofi 720

14.16.1 Company Overview 720

14.16.2 Sanofi: Revenue Analysis 720

14.16.3 Product Portfolio 721

14.16.4 Recent Developments 721

14.17 Terumo Corporation 723

14.17.1 Company Overview 723

14.17.2 Terumo Corporation: Revenue Analysis 723

14.17.3 Product Portfolio 723

14.17.4 Recent Developments 724

14.18 Teva Pharmaceutical 726

14.18.1 Company Overview 726

14.18.1.1 Drivers Explained 727

14.18.1.2 Weaknesses Explained 727

14.18.1.3 Oppurtunities Explained 727

14.18.1.4 Threats Explained 728

14.18.2 Teva Pharmaceutical: Revenue Analysis 729

14.18.3 Product Portfolio 731

14.18.4 Recent Developments 732

14.19 West Pharmaceutical Services, Inc 735

14.19.1 Company Overview 735

14.19.2 West Pharmaceutical Services, Inc: Revenue Analysis 735

14.19.3 Product Portfolio 736

14.19.4 Recent Developments 737

?

14.20 Ypsomed Holding Ag 738

14.20.1 Company Overview 738

14.20.2 Ypsomed Holding Ag: Revenue Analysis 738

14.20.3 Product Portfolio 738

14.20.4 Recent Developments 739

15 Related Reports 741


List Of Figure

List Of Figures

Figure 1 Global Injectable Drug Delivery Market: Segmentation 63

Figure 2 Global Injectable Drug Delivery Market: Geographic Scope 64

Figure 3 Global Injectable Drug Delivery Market: Data Triangulation 66

Figure 4 Global Injectable Drug Delivery Market: Research Snapshot 67

Figure 5 Global Injectable Drug Delivery Market: Bottom Up Approach 67

Figure 6 Global Injectable Drug Delivery Market: Top Down Approach 68

Figure 7 Global Injectable Drug Delivery Market: Interview Demographics 69

Figure 8 Figure: Drivers, Restraints, Opportunities And Challenges Of The Injectable Drug Delivery Market 72

Figure 9 Number Of Needlestick Injuries 77

Figure 10 North America Is Expected To Dominate The Market For Injectable Drug Delivery In 2017 And Apac Is Expected To Be Growing With The Highest Cagr In The Forecast Period To 2025 87

Figure 11 Technological Development And Increasing Prevalence Of Chronic Diseases Are Expected To Drive The Market For Injectable Drug Delivery In The Forecast Period 2018 To 2025 88

Figure 12 Injectable Drug Delivery Formulation Market Segment Is Expected To Account For The Largest Share Of The Global Injectable Drug Delivery Market In 2018 & 2025 89

Figure 13 North America Is The Highest Growing And Most Profitable Revenue Pockets For Injectable Drug Delivery Manufacturers In The Forecast Period To 2018 To 2025 90

Figure 14 Global Injectable Drug Delivery Market: By Type, Snapshot 2017 92

Figure 15 Global Injectable Drug Delivery Market: By Application, Snapshot 2017 131

Figure 16 Global Injectable Drug Delivery Market: By Usage Pattern, Snapshot 2017 155

Figure 17 Global Injectable Drug Delivery Market: By Mode Of Administration, Snapshot 2017 160

Figure 18 Global Injectable Drug Delivery Market Dominated By Hospital And Cliinics Segment 165

Figure 19 Global Injectable Drug Deliverymarket: By End-User, Snapshot 2017 166

Figure 20 Global Injectable Drug Delivery Market: By Distribution Channel, Snapshot 2017 171

Figure 21 North America Injectable Drug Delivery Market Snapshot (2017) 177

Figure 22 Europe Injectable Drug Delivery Market Snapshot (2017) 242

Figure 23 Asia-Pacific Injectable Drug Delivery Market Snapshot (2017) 418

Figure 24 South America Injectable Drug Delivery Market Snapshot (2017) 589

Figure 25 Middle East And Africa Injectable Drug Delivery Market Snapshot (2017) 623

Figure 26 Global Injectable Drug Delivery Market: Company Share 2017 (%) 657

Figure 27 Becton, Dickinson And Company: Swot (Strength, Weakness, Opportunities And Threats) 658

Figure 28 Pfizer, Inc.: Swot (Strength, Weakness, Opportunities And Threats) 665

Figure 29 Baxter International Inc.: Swot (Strength, Weakness, Opportunities And Threats) 674

Figure 30 Eli Lilly And Company: Swot (Strength, Weakness, Opportunities And Threats) 697

Figure 31 Teva Pharmaceutical: Swot (Strength, Weakness, Opportunities And Threats) 726

Licence Rights

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies


Companies

key market players for global injectable drug delivery market are listed below:

Baxter International, Inc.,

Becton Dickinson and Company,

Gerresheimer AG,

Pfizer, Inc.,

Schott AG,

Alkermes Plc.,

Eli Lilly and Company,

Sandoz,

Terumo Corporation,

Teva Pharmaceuticals Industries Ltd.

Ypsomed,

Bespak

Global injectable drug delivery market is expected to reach USD 1,104,096.5 million by 2025 from USD 378,998.2 million in 2017, at a CAGR of 12.4% in the forecast period 2018 to 2025

The major factors contributing to the growth of the market includes factors such rising cases of chronic diseases and due to rising demand of self-injection devices. On the other hand needle stick injuries and infections may hinder the growth of the market.

The key market players for global injectable drug delivery market are listed below:

Baxter International, Inc.,

Becton Dickinson and Company,

Gerresheimer AG,

Pfizer, Inc.,

Schott AG,

Alkermes Plc.,

Eli Lilly and Company,

Sandoz,

Terumo Corporation,

Teva Pharmaceuticals Industries Ltd.

Ypsomed,

Bespak

The market is further segmented into:

Type

Usage Pattern

End-User

Mode of Administration

Distribution Channel

Application

Geography

The global injectable drug delivery market is segmented on of type, portability, type, product type, application, usage pattern, mode of administration, end user, distribution channel, and geography. The report provides data for 2016 to 2025, 2017 being the current year while 2018 to 2025 is the forecast period for the report.

The global injectable drug delivery market is segmented based on type into two notable segments; injectable drug delivery device and injectable drug delivery formulation. Injectable drug delivery device market is segmented into conventional injection devices and self-injection devices. The injectable drug delivery formulation is segmented into conventional drug delivery formulation and novel drug delivery formulation. The Injectable drug delivery market is dominated by formulations with 75.7% market share in 2018, growing at a CAGR of 12.4% and will cross USD 837,873.64 million by 2025

On the basis of application, the market is segmented into autoimmune disease, hormonal disorders, orphan diseases, oncology and others. The autoimmune diseases segment is further sub segmented based on indications into rheumatoid arthritis, multiple sclerosis, Crohn's disease, psoriasis and others. Hormonal disorders are further segmented into indications such as diabetes, antithrombotic therapy, reproductive health diseases, anemia, osteoporosis and others. The Injectable drug delivery market is dominated by hormonal disorders with 50.1% market share in 2018, growing at a CAGR of 12.1% and will cross USD 540,977.35 million by 2025. However, oncology segment is expected to grow at the highest CAGR of 13.6% in the forecast period, and is expected to reach USD 265,145.17 million in 2025 from USD 82,915.00 million in 2017

On the basis of usage pattern, the market is segmented into curative care, immunization and other usage pattern. The Injectable drug delivery market is dominated by curative care with 93.2% market share in 2018, growing at a CAGR of 12.5% and will cross USD 1,036,829.49 million by 2025.

On the basis of mode of administration, the market is segmented into skin, circulatory/muskoskeletal, organs and central nervous system. The Injectable drug delivery market is dominated by skin with 46.8% market share in 2018, growing at a CAGR of 12.8% and will cross USD 532,193.0 million by 2025.

On the basis of end users, the market is classified into hospitals and clinics, home healthcare, research laboratories, pharmaceutical and biotechnological companies and others. The Injectable drug delivery market is dominated by hospitals & clinics with 62.6% market share in 2018, growing at a CAGR of 12.5% and will cross USD 693,323.05 million by 2025.

On the basis of distribution channel, the market is classified into hospital pharmacies, pharmacy store, and direct tender and online pharmacy. The Injectable drug delivery market is dominated by direct tenders with 69.2% market share in 2018, growing at a CAGR of 12.7% and will cross USD 780,682.75 million by 2025. However, pharmacy stores segment is expected to grow at the highest CAGR of 13.5% in the forecast period, and is expected to reach USD 142,617.48 million in 2025 from USD 44,812.56 million in 2017

Based on geography, the market is segmented into 5 geographical regions, North America, Europe, Asia-Pacific, South America and Middle East and Africa. The geographical regions are further segmented into 24 major countries such as U.S. Canada, Mexico, Germany, France, U.K., Belgium, Switzerland, Belgium, Turkey, Japan, China, Singapore, Brazil, India, Russia, South Africa and many others.

Based on geography, the Global injectable drug delivery market is segmented into geographical regions, such as,

North- America

South America

Europe

Asia-Pacific

Middle East and Africa

Covered in this report

The report covers the present scenario and the growth prospects of the global injectable drug delivery market for 2018-2025. To calculate the market size, the report considers the revenue generated from the sales of the web conferencing and unified communication and collaboration (UC&C) and video conferencing, secondary resources and doing in-depth company share analysis of major 10 players in the market.

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

READ MORE

Scope

Table Of Contents

1 Introduction 58

1.1 Overview Of Global Injectable Drug Delivery Market 58

1.2 Currency And Pricing 59

1.3 Limitation 59

1.4 Markets Covered 60

2 Market Segmentation 63

2.1 Markets Covered 63

2.2 Geographic Scope 64

2.3 Years Considered For The Study 65

2.4 Currency And Pricing 65

2.5 Research Methodology 66

2.6 Primary Interviews With Key Opinion Leaders 69

2.7 Secondary Sources 70

2.8 Assumptions 70

3 Market Overview 71

3.1 Drivers 73

3.1.1 Rising Cases Of Chronic Diseases 73

3.1.2 Rising Demand Of Self-Injection Devices 75

3.1.3 Growth Of Biologics Market 75

3.1.4 Technological Advancements And Innovations In Drug Delivery Market 76

3.2 Restraints 77

3.2.1 Needlestick Injuries And Infections 77

3.2.2 High Cost Of Development 78

3.2.3 Strict Regulatory Framework 79

3.3 Opportunity 80

3.3.1 Increasing Demand For Generic And Biosimilar Drugs 80

3.3.1.1 Generics 80

3.3.1.2 Biosimilars 80

3.3.2 Increasing Demand For Contraceptive Injectables 81

3.3.3 Increasing Demand For Self-Administration Of Drugs 82

3.4 Challenges 83

3.4.1 Alternative Route Of Drug Administration 83

3.4.2 Product Recall 84

3.4.3 Stability Of Products 84

3.4.4 Sterility Of Injections 85

4 Executive Summary 86

5 Premium Insights 88

?

6 Global Injectable Drug Delivery Market, By Type 91

6.1 Overview 92

6.2 Injectable Drug Delivery Devices 93

6.2.1 Conventional Injection Devices 94

6.2.1.1 Conventional Injection Devices, By Material 94

6.2.1.1.1 Glass 95

6.2.1.1.2 Plastic 95

6.2.1.2 Conventional Injection Devices, By Product 96

6.2.1.2.1 Fillable Syringes 96

6.2.1.2.2 Prefilled Syringes 96

6.2.1.3 Conventional Injection Devices, By Usability 98

6.2.1.3.1 Reusable Syringes 98

6.2.1.3.2 Disposable Syringes 98

6.2.2 Self Injection Devices 99

6.2.2.1 Needle Free Injectors (Nfi) 100

6.2.2.2 Needle Free Injectors, By Product 101

6.2.2.2.1 Fillable Needle-Free Injectors 101

6.2.2.2.2 Prefilled Needle-Free Injectors 101

6.2.2.3 Needle Free Injectors, By Technology 101

6.2.2.3.1 Jet Based Needle Free Injectors: 102

6.2.2.3.2 Spring Based Needle Free Injectors: 102

6.2.2.3.3 Laser Based Needle Free Injectors: 103

6.2.2.3.4 Vibration Based Needle Free Injectors: 103

6.2.2.4 Needle Free Injectors, By Usability 103

6.2.2.4.1 Reusable Needle-Free Injectors 103

6.2.2.4.2 Disposable Needle-Free Injectors 104

6.2.2.5 Auto Injectors 105

6.2.2.6 Auto Injectors, By Product 105

6.2.2.6.1 Fillable Auto Injectors 105

6.2.2.6.2 Pre-Filled Autoinjectors 105

6.2.2.7 Auto Injectors, By Technology 106

6.2.2.7.1 Automated Auto Injectors 106

6.2.2.7.2 Manual Auto Injectors 106

6.2.2.8 Auto Injectors, By Design 107

6.2.2.8.1 Standardized Auto Injectors 107

6.2.2.8.2 Automated Autoinjectors 107

6.2.2.9 Auto Injectors, By Usability 108

6.2.2.9.1 Reusable Autoinjectors 108

6.2.2.9.2 Disposable Autoinjectors 108

6.2.2.10 Pen Injectors 109

?

6.2.2.11 Pen Injectors, By Product 109

6.2.2.11.1 Single Chambered Pen Injectors 110

6.2.2.11.2 Dual Chambered Pen Injectors 110

6.2.2.12 Pen Injectors, By Design 111

6.2.2.12.1 Standard Pen Injectors 111

6.2.2.12.2 Customized Pen Injectors 111

6.2.2.13 Pen Injectors, By Usability 111

6.2.2.13.1 Reusable Pen Injectors 111

6.2.2.13.2 Disposable Pen Injectors 112

6.2.2.14 Wearable Injectors 113

6.2.2.14.1 Other Devices 113

6.3 Injectable Drug Delivery Formulation 114

6.3.1 Conventional Drug Delivery Formulations 114

6.3.1.1 Solutions 115

6.3.1.2 Reconstituted/Lyophilized Formulations 115

6.3.1.3 Suspensions 116

6.3.1.4 Emulsions 117

6.3.2 Novel Drug Delivery Formulations 118

6.3.2.1 Colloidal Dispersions 120

6.3.2.1.1 Niosomes 121

6.3.2.1.2 Liposomes 121

6.3.2.1.3 Polymeric Mixed Micelles 122

6.3.2.1.4 Nanoparticles 123

6.3.2.1.5 Nanosuspensions 124

6.3.2.1.6 Nanoemulsions/Microemulsions 124

6.3.2.1.7 Solid Lipid Nanoparticles 125

6.3.2.2 Microparticles 126

6.3.2.2.1 Microspheres 126

6.3.2.2.2 Microcapsules 127

6.3.2.3 Long Acting Injection Formulation 128

7 Global Injectable Drug Delivery Market, By Application 130

7.1 Overview 131

7.2 Global Injectable Drug Delivery Market, By Application 132

7.3 Hormonal Disorders 133

7.3.1 Injectable Drugs For Diabetes 133

7.3.2 Injectable Drugs For Anemia 134

7.3.3 Injectable Drugs For Reproductive Health Disease 134

7.3.4 Injectable Drugs For Antithrombotic/Thrombolytic Therapy 136

7.3.5 Injectable Drugs For Osteoporosis 136

7.3.6 Injectable Drugs For Growth Hormone Disorders (Ghd) 137

?

7.4 Oncology 139

7.5 Autoimmune Diseases 141

7.5.1 Injectable Drugs For Rheumatoid Arthritis 141

7.5.2 Injectable Drugs For Multiple Sclerosis 142

7.5.3 Injectable Drugs For Crohn'S Diseases 143

7.5.4 Injectable Drugs For Psoriasis 144

7.5.5 Injectable Drugs For Other Autoimmune Diseases 145

7.6 Orphan Disease 146

7.7 Other Applications 148

7.7.1 Injectable Drugs For Pain Management 148

7.7.2 Injectable Drugs For Allergy Treatment 149

7.7.3 Injectable Drugs For Aesthetic Treatments 150

7.7.4 Injectable Drugs For Hepatitis C 151

7.7.5 Injectable Drugs For Hemophilia 152

8 Global Injectable Drug Delivery Market, By Usage Pattern 154

8.1 Overview 155

8.2 Curative Care 156

8.3 Immunizations 157

8.4 Other Usage Pattern 157

9 Global Injectable Drug Delivery Market, By Mode Of Administration 159

9.1 Overview 160

9.2 Skin 161

9.3 Circulatory/ Muskoskeletal 161

9.4 Organs 162

9.5 Central Nervous System 162

10 Global Injectable Drug Delivery Market, By End User 164

10.1 Overview 165

10.2 Hospitals And Clinics 167

10.3 Home Healthcare Settings 167

10.4 Research Laboratories 167

10.5 Pharmaceutical And Biotechnological Companies 168

10.6 Other End Users 169

11 Global Injectable Drug Delivery Market, By Distribution Channel 170

11.1 Overview 171

11.1.1 Hospital Pharmacy 172

11.1.2 Pharmacy Stores 172

11.1.3 Direct Tender 172

11.1.4 Online Pharmacy 172

?

12 Global Injectable Drug Dilivery Market By Geography 174

12.1 Overview 174

12.2 North America 176

12.2.1 U.S. 194

12.2.2 Canada 209

12.2.3 Mexico 225

12.3 Europe 241

12.3.1 Germany 259

12.3.2 France 274

12.3.3 U.K. 291

12.3.4 Italy 306

12.3.5 Switzerland 322

12.3.6 Spain 338

12.3.7 Netherland 354

12.3.8 Russia 371

12.3.9 Turkey 385

12.3.10 Belgium 400

12.3.11 Rest Of Europe 417

12.4 Asia-Pacific 418

12.4.1 Japan 436

12.4.2 China 452

12.4.3 India 467

12.4.4 South Korea 482

12.4.5 Australia 497

12.4.6 Thailand 512

12.4.7 Malaysia Injectable Drug Delivery Market 528

12.4.8 Singapore 543

12.4.9 Indonesia 558

12.4.10 Phillippines 573

12.4.11 Rest Of Asia-Pacific Injectable Drug Delivery Market 588

12.5 South America 589

12.5.1 Brazil 606

12.5.2 Rest Of South Africa 622

12.6 Middle East & Africa 623

12.6.1 South Africa Injectable Drug Delivery Market 640

12.6.2 Rest Of Middle East& Africa Injectable Drug Delivery Market 656

13 Global Injectable Drug Delivery Market, Company Share 657

13.1 Company Share Analysis: Global 657

?

14 Company Profiles 658

14.1 Becton, Dickinson And Company 658

14.1.1 Company Overview 658

14.1.1.1 Drivers Explained 659

14.1.1.2 Weaknesses Explained 659

14.1.1.3 Oppurtunities Explained 659

14.1.1.4 Threats Explained 660

14.1.2 Becton, Dickinson And Company: Revenue Analysis 660

14.1.3 Product Portfolio 662

14.1.4 Recent Developments 663

14.2 Pfizer 665

14.2.1 Company Overview 665

14.2.1.1 Drivers Explained 666

14.2.1.2 Weaknesses Explained 666

14.2.1.3 Oppurtunities Explained 667

14.2.1.4 Threats Explained 668

14.2.2 Pfizer, Inc.: Revenue Analysis 668

14.2.3 Product Portfolio 669

14.2.4 Recent Developments 671

14.3 Baxter International, Inc. 674

14.3.1 Company Overview 674

14.3.1.1 Drivers Explained 675

14.3.1.2 Weaknesses Explained 676

14.3.1.3 Oppurtunities Explained 676

14.3.1.4 Threats Explained 676

14.3.2 Baxter International: Revenue Analysis 677

14.3.3 Product Portfolio 679

14.3.4 Recent Developments 679

14.4 Gerresheimer Ag 681

14.4.1 Company Overview 681

14.4.2 Gerresheimer Ag: Revenue Analysis 681

14.4.3 Product Portfolio 682

14.4.4 Recent Developments 682

14.5 Schott Ag Inc. 683

14.5.1 Company Overview 683

14.5.2 Schott Ag Inc: Revenue Analysis 683

14.5.3 Product Portfolio 684

14.5.4 Recent Developments 684

?

14.6 Alkermes Inc. 686

14.6.1 Company Overview 686

14.6.2 Alkermes Inc.: Revenue Analysis 686

14.6.3 Product Portfolio 686

14.6.4 Recent Developments 687

14.7 Antares Pharma 689

14.7.1 Company Overview 689

14.7.2 Antares Pharma: Revenue Analysis 689

14.7.3 Product Portfolio 690

14.7.4 Recent Developments 691

14.8 Bespak (Subsidiary Of Consort Medical Company) 692

14.8.1 Company Overview 692

14.8.2 Bespak (Subsidiary Of Consort Medical Company): Revenue Analysis 692

14.8.3 Product Portfolio 693

14.8.4 Recent Developments 693

14.9 Elcam Medical 695

14.9.1 Company Overview 695

14.9.2 Elcam Medical: Company Snapshot 695

14.9.3 Product Portfolio 696

14.9.4 Recent Developments 696

14.10 Eli Lilly And Company 697

14.10.1 Company Overview 697

14.10.1.1 Drivers Explained 698

14.10.1.2 Weaknesses Explained 698

14.10.1.3 Oppurtunities Explained 699

14.10.1.4 Threats Explained 700

14.10.2 Eli Lilly And Company : Revenue Analysis 700

14.10.3 Product Portfolio 702

14.10.4 Recent Developments 703

14.11 Haselmeier 705

14.11.1 Company Overview 705

14.11.2 Haselmeier: Company Snapshot 705

14.11.3 Product Portfolio 705

14.11.4 Recent Developments 706

14.12 Mylan N.V. 707

14.12.1 Company Overview 707

14.12.2 Mylan N.V.: Revenue Analysis 707

14.12.3 Product Portfolio 708

14.12.4 Recent Developments 708

?

14.13 Novo Nordisk 711

14.13.1 Company Overview 711

14.13.2 Novo Nordisk: Revenue Analysis 711

14.13.3 Product Portfolio 712

14.13.4 Recent Developments 713

14.14 Owen Mumford Ltd 715

14.14.1 Company Overview 715

14.14.2 Owen Mumford Ltd: Company Snapshot 715

14.14.3 Product Portfolio 716

14.14.4 Recent Developments 716

14.15 Sandoz International Gmbh 718

14.15.1 Company Overview 718

14.15.2 Sandoz International Gmbh: Revenue Analysis 718

14.15.3 Product Portfolio 718

14.15.4 Recent Developments 719

14.16 Sanofi 720

14.16.1 Company Overview 720

14.16.2 Sanofi: Revenue Analysis 720

14.16.3 Product Portfolio 721

14.16.4 Recent Developments 721

14.17 Terumo Corporation 723

14.17.1 Company Overview 723

14.17.2 Terumo Corporation: Revenue Analysis 723

14.17.3 Product Portfolio 723

14.17.4 Recent Developments 724

14.18 Teva Pharmaceutical 726

14.18.1 Company Overview 726

14.18.1.1 Drivers Explained 727

14.18.1.2 Weaknesses Explained 727

14.18.1.3 Oppurtunities Explained 727

14.18.1.4 Threats Explained 728

14.18.2 Teva Pharmaceutical: Revenue Analysis 729

14.18.3 Product Portfolio 731

14.18.4 Recent Developments 732

14.19 West Pharmaceutical Services, Inc 735

14.19.1 Company Overview 735

14.19.2 West Pharmaceutical Services, Inc: Revenue Analysis 735

14.19.3 Product Portfolio 736

14.19.4 Recent Developments 737

?

14.20 Ypsomed Holding Ag 738

14.20.1 Company Overview 738

14.20.2 Ypsomed Holding Ag: Revenue Analysis 738

14.20.3 Product Portfolio 738

14.20.4 Recent Developments 739

15 Related Reports 741


List Of Figure

List Of Figures

Figure 1 Global Injectable Drug Delivery Market: Segmentation 63

Figure 2 Global Injectable Drug Delivery Market: Geographic Scope 64

Figure 3 Global Injectable Drug Delivery Market: Data Triangulation 66

Figure 4 Global Injectable Drug Delivery Market: Research Snapshot 67

Figure 5 Global Injectable Drug Delivery Market: Bottom Up Approach 67

Figure 6 Global Injectable Drug Delivery Market: Top Down Approach 68

Figure 7 Global Injectable Drug Delivery Market: Interview Demographics 69

Figure 8 Figure: Drivers, Restraints, Opportunities And Challenges Of The Injectable Drug Delivery Market 72

Figure 9 Number Of Needlestick Injuries 77

Figure 10 North America Is Expected To Dominate The Market For Injectable Drug Delivery In 2017 And Apac Is Expected To Be Growing With The Highest Cagr In The Forecast Period To 2025 87

Figure 11 Technological Development And Increasing Prevalence Of Chronic Diseases Are Expected To Drive The Market For Injectable Drug Delivery In The Forecast Period 2018 To 2025 88

Figure 12 Injectable Drug Delivery Formulation Market Segment Is Expected To Account For The Largest Share Of The Global Injectable Drug Delivery Market In 2018 & 2025 89

Figure 13 North America Is The Highest Growing And Most Profitable Revenue Pockets For Injectable Drug Delivery Manufacturers In The Forecast Period To 2018 To 2025 90

Figure 14 Global Injectable Drug Delivery Market: By Type, Snapshot 2017 92

Figure 15 Global Injectable Drug Delivery Market: By Application, Snapshot 2017 131

Figure 16 Global Injectable Drug Delivery Market: By Usage Pattern, Snapshot 2017 155

Figure 17 Global Injectable Drug Delivery Market: By Mode Of Administration, Snapshot 2017 160

Figure 18 Global Injectable Drug Delivery Market Dominated By Hospital And Cliinics Segment 165

Figure 19 Global Injectable Drug Deliverymarket: By End-User, Snapshot 2017 166

Figure 20 Global Injectable Drug Delivery Market: By Distribution Channel, Snapshot 2017 171

Figure 21 North America Injectable Drug Delivery Market Snapshot (2017) 177

Figure 22 Europe Injectable Drug Delivery Market Snapshot (2017) 242

Figure 23 Asia-Pacific Injectable Drug Delivery Market Snapshot (2017) 418

Figure 24 South America Injectable Drug Delivery Market Snapshot (2017) 589

Figure 25 Middle East And Africa Injectable Drug Delivery Market Snapshot (2017) 623

Figure 26 Global Injectable Drug Delivery Market: Company Share 2017 (%) 657

Figure 27 Becton, Dickinson And Company: Swot (Strength, Weakness, Opportunities And Threats) 658

Figure 28 Pfizer, Inc.: Swot (Strength, Weakness, Opportunities And Threats) 665

Figure 29 Baxter International Inc.: Swot (Strength, Weakness, Opportunities And Threats) 674

Figure 30 Eli Lilly And Company: Swot (Strength, Weakness, Opportunities And Threats) 697

Figure 31 Teva Pharmaceutical: Swot (Strength, Weakness, Opportunities And Threats) 726

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Companies

key market players for global injectable drug delivery market are listed below:

Baxter International, Inc.,

Becton Dickinson and Company,

Gerresheimer AG,

Pfizer, Inc.,

Schott AG,

Alkermes Plc.,

Eli Lilly and Company,

Sandoz,

Terumo Corporation,

Teva Pharmaceuticals Industries Ltd.

Ypsomed,

Bespak

chat_bubbleLet's Chat